Merck & Co
(NYSE:MRK)
$126.02
0.79[0.63%]
Last update: 3:35PM Get Real Time Here
Q1 2024 Earnings in 6 days from now on Thu Apr 25th, before the market open
Conference call scheduled in 6 days at 9:00 AM Click to view the webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
50%
Overview Rating
Speculative
Technicals Analysis
100
0100
Financials Analysis
20
0100

Merck & Co Stock (NYSE:MRK), Quotes and News Summary

Merck & Co Stock (NYSE: MRK) stock price, news, charts, stock research, profile.

Open$125.650
Close-
Volume / Avg.6.178M / 8.336M
Day Range124.890 - 126.085
52 Wk Range99.140 - 133.100
Market Cap$319.212B
P/E Ratio894.500
Dividend Yield2.460%
ExchangeNYSE
RSI
49
Short Interest
0.77%
Days to Cover2.01

Recent News

Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government stalled despite incentives.
Vandana Singh
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
Shares of Moderna (NASDAQ: MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy, in certain patients with head and neck cancer.
Zacks
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.
Vandana Singh
20%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
3
Jan
6
1
Feb
3
1
1
Mar
4
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
About Merck & Co Inc
Sector
Health Care
Industry
Pharmaceuticals
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, in...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
MRK
NVO

FAQ

Q

How do I buy Merck & Co (MRK) stock?

A

You can purchase shares of Merck & Co (NYSE: MRK) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Merck & Co's (MRK) competitors?

A

Other companies in Merck & Co’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), Pfizer (NYSE:PFE) and Axsome Therapeutics (NASDAQ:AXSM).

Q

What is the target price for Merck & Co (MRK) stock?

A

The latest price target for Merck & Co (NYSE: MRK) was reported by Cantor Fitzgerald on Thursday, April 18, 2024. The analyst firm set a price target for 135.00 expecting MRK to rise to within 12 months (a possible 7.13% upside). 40 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Merck & Co (MRK)?

A

The stock price for Merck & Co (NYSE: MRK) is $126.02 last updated Today at April 19, 2024 at 3:35 PM EDT.

Q

Does Merck & Co (MRK) pay a dividend?

A

A quarterly cash dividend of $0.77 per share of Class A Common Stock. The quarterly cash dividend was payable on April 5, 2024 to stockholders of record on March 14, 2024.

Q

When is Merck & Co (NYSE:MRK) reporting earnings?

A

Merck & Co’s Q1 earnings are confirmed for Thursday, April 25, 2024.

Q

Is Merck & Co (MRK) going to split?

A

There is no upcoming split for Merck & Co.

Q

What sector and industry does Merck & Co (MRK) operate in?

A

Merck & Co is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.

People Also Watch